Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...

DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, ...

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific ...

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...

Citizens increased the price target for Abivax SA (NASDAQ: ABVX) from $114 to $131. Citizens analyst Jason Butler maintained a Market Outperform rating. Abivax shares settled at $117.91 on Monday. See ...

Abivax CEO Marc de Garidel discusses the future growth of the company, after this year's meteoric rally. Massive data breach ...

Investing.com -- Abivax SA (EPA: ABVX) shares dipped after the company reported a wider net loss for the first nine months ...

Abivax SA Sponsored ADR ( ($ABVX) ) has provided an announcement. On December 15, 2025, Abivax SA announced its financial results for the third ...

Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027 PARIS, France, December 15, 2025, 10:05 p.m. CET ...

This article first appeared on GuruFocus. Abivax SA (XPAR:ABVX) is set to release its Q3 2025 earnings on Dec 15, 2025. The ...

Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...

Abivax stock skyrocketed in July after the company announced overwhelmingly positive topline results from its Phase 3 ...